04:26 AM EST, 02/24/2025 (MT Newswires) -- Takeda Pharmaceutical Co ( TAK ) said Monday that the European Medicines Agency has approved an additional subcutaneous administration option for hereditary angioedema drug TAKHZYRO, or lanadelumab.

The drug now comes in a 2 mL pre-filled pen for adolescent and adult patients, the company said.

Hereditary angioedema is a rare genetic disease that causes severe swelling in the body.